newsfilter
← Latest News
GlobeNewswire·

Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today